The report for Global urinalysis test market by Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance.
The global urinalysis test market is expected to grow at a CAGR of 6.3% during the forecast period.
Urinalysis is a urine test to detect and manage disorders such as urinary tract infections (UTIs), liver disease, kidney disease, and diabetes. It is a non-invasive and cost-effective method of analysis. It involves checking the appearance, content, and concentration of urine. The test is mostly recommend during pregnancy checkup, routine examination, and pre-surgery preparation to detect any disease condition. In case of diabetes, urinalysis is used only for monitoring the glucose level and not for diagnosis.
The market for urinalysis test is expected to show exponential growth owing to increasing demand for point of care testing devices, rising prevalence of chronic diseases, and developing technology in the field of diagnostics. Another factor contributing to the market growth is cost-effectiveness of the test and higher demand for urine automated urine analyzers.
Furthermore, the growth of the market is affected by the lack of trained professionals and stringent regulations governing the manufacturing and the sales of chemistry analyzers across the globe.
According to the world Health Organization (WHO), about 59% of the mortality across the globe is due to chronic diseases and almost 35 million people die of the chronic diseases
Key Players in the Global Urinalysis Test Market are: Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), and ACON Laboratories, Inc. (U.S.).
Get Sample copy at https://www.marketresearchfuture.com/sample_request/839 .
- Consumables segment accounted for the largest market share in 2016
- The global urinalysis test market by test type is expected to reach USD 698.85 million by 2023
- Sediments/microscopic urinalysis is the fastest growing segment, which is projected to grow at a CAGR of 7.13% % during the forecast period of 2017-2023
- Pregnancy tests segment accounted for the largest market share in 2016
- American region captures the major market share and is expected to reach USD 594.21 million by 2023
The global urinalysis test market is segmented on the basis of product type, test type, application, and end user.
On the basis of product type, the market is segmented into instruments and consumables. The instruments type includes urine chemistry analyzer such as automatic urine analyzers and semi-automatic urine analyzers, automated urine sediment analyzers, point-of-care devices, and strip analyzer. The consumables are further segmented into plastic consumables, test strips, and chemical agents.
On the basis of test type, the market is segmented into macroscopic urinalysis, biochemical urinalysis, and sediments/microscopic urinalysis.
On the basis of application, the market is segmented into disease diagnosis including the diagnosis of diseases such as kidney disease, liver disease, diabetes, pregnancy tests, and others.
On the basis of end users, the market is segmented into hospitals, independent laboratories, and physician practices.
Regional Analysis of the Global Urinalysis Test Market
The Americas is the largest market for urinalysis test owing to the rising demand for automated urine analyzers, technological advancement, and rising prevalence of kidney and liver diseases. In North America, the U.S. holds the largest share of the global market owing to the concentration of the major players manufacturing urine analyzers and consumables across the globe.
Europe is the second largest market for urinalysis test, which is expected to grow continuously at the steady growth rate in the near future due to increased prevalence of chronic diseases such as diabetes, availability of cost-effective treatments, and growth in the government funding for research and development activities. According to the World Health Organization, about 60 million European have diabetes and the prevalence of diabetes is relatively high among people over 25 years in this region.
In Asia Pacific, the market is expected grow at a fastest rate owing to an increasing prevalence of chronic disease such as diabetes, kidney diseases, and others, changing lifestyle, and rising demand for urine analyzers by the healthcare providers. Furthermore, diabetes is one of major the health problems among the geriatric population.
The Middle East & Africa also shows a steady rise in the market owing to rising demand for diagnostic solutions and point of care testing devices.
TABLE OF CONTENTS
Top of Form
1 REPORT PROLOGUE
2 MARKET INTRODUCTION
2.1 Introduction 17
2.2 Scope Of Study 17
2.3 Research Objective 17
2.4 Assumptions & Limitations 18
2.4.1 Assumptions 18
2.4.2 Limitations 18
2.5 Market Structure 18
3 RESEARCH METHODOLOGY
3.1.1 Primary Research Methodology 20
3.1.2 Secondary Research Methodology 21
3.1.3 Market Share Analysis 22
3.1.4 Trade Analysis 22
3.2 Forecast Model 23
4 MARKET DYNAMICS
4.1 Introduction 24
4.2 Drivers 25
4.2.1 Rising Demand For Point-Of-Care Testing: (35%) 25
4.2.2 Rising Prevalence Of Chronic Diseases: (40%) 26
4.2.3 Technological Advancements: (25%) 27
4.3 Restraints 28
4.3.1 Stringent Regulations: (60%) 28
4.3.2 Lack Of Trained Professionals: (40%) 29
4.4 Mega Trends 30
4.5 Macroeconomic Indicators 30
4.6 Technology Trends And Assessment 32
5 MARKET FACTOR ANALYSIS
5.1 Value Chain Analysis 33
Get Discount at https://www.marketresearchfuture.com/check-discount/839 .
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Market Research Future
+1 646 845 9312